Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Endometrial Cancer

Presenters

Shin Nishio

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

S. Nishio1, K. Murotani2, W. Yamagami3, S. Suzuki4, H. Nakai5, K. Kato6, H. Tokunaga7, H. Nomura8, Y. Yokoyama9, K. Takehara10

Author affiliations

  • 1 Obstetrics And Gynecology, Kurume University, 830-0011 - Kurume/JP
  • 2 Biostatistics Center, Kurume University Hospital, 830-0011 - Kurume/JP
  • 3 Obstetrics And Gynecology, Keio University School of Medicine, 160-8582 - Shinjuku-ku/JP
  • 4 Gynecology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 5 Obstetrics And Gynecology, Kindai University - Faculty of Medicine, 589-8511 - Osaka/JP
  • 6 Obstetrics And Gynecology, Kitasato University School of Medicine, Sagamihara/JP
  • 7 Obstetrics And Gynecology, Tohoku University School of Medicine, 980-8574 - Sendai/JP
  • 8 Obstetrics And Gynecology, Fujita Health University, Toyoake/JP
  • 9 Obstetrics And Gynecology, Hirosaki University Graduate School of Medicine, 036-8562 - Hirosaki/JP
  • 10 Gynecologic Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 803P

Background

Japanese Gynecologic Oncology Group (JGOG) 2043 was a trial to assess the efficacy of three different chemotherapeutic regimens as adjuvant therapy in endometrial cancer (EC) patients with post-operative recurrent risk. Inflammation predisposes patients to tumorigenesis by damaging DNA, stimulating angiogenesis, and potentiating pro-proliferative and anti-apoptotic processes. This study investigated whether pre-treatment systemic inflammatory markers (PTSIMs) are associated with survival outcomes in EC.

Methods

Women with EC were recruited to the JGOG 2043 study, excluding patients who did not receive chemotherapy and those lost to follow-up. PTSIMs, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and hemoglobin, albumin, lymphocyte, and platelet (HALP) score were analysed in terms of clinicopathological factors, progression-free survival (PFS), and overall survival (OS). Optimal cut-off values for NLR, PLR, and HALP score were determined using the web application Cutoff Finder for PFS and OS. Survival estimates were calculated using the Kaplan–Meier method. Differences in survival between groups were assessed using a log-rank test.

Results

In total, 712 patients were enrolled in the JGOG 2043 study, with a median age of 59 years (interquartile range (IQR), 52–64) and body mass index (BMI) of 22.4 kg/m2 (IQR 19–25). The optimal cut-off values for PFS were 1.478 for NLR, 0.01695 for PLR, and 35.52 for HALP score. Similarly, the optimal cut-off values for OS were 1.88 for NLR, 0.02623 for PLR, and 19.87 for HALP score. Regarding the optimal cut-off values for PFS, NLR was associated with BMI; PLR with age, BMI, and surgical stage; and HALP score with BMI, surgical stage, and lymph node metastasis. For the optimal cut-offs for OS, NLR was associated with BMI, PLR, and BMI; and HALP score was associated with age and BMI. In PFS, HALP score was the prognostic factor (NLR: p=0.068; PLR: p=0.086; HALP score: p=0.025). In OS, PLR and HALP score were prognostic factors (NLR: p=0.1; PLR: p=0.028; HALP score: p=0.028).

Conclusions

PTSIMs are associated with survival outcomes in EC. In particular, HALP score was a prognostic factor for both PFS and OS.

Clinical trial identification

UMIN000036755.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.